Aytu Biopharma Inc Up 19.79% To $2.30 After Earnings Beat

Aytu Biopharma Inc (AYTU) surpassed earnings projections on 9/27/2023 for Q4 2023.

Aytu Biopharma Inc's earnings came in at an EPS loss of $0.59 per share, 38.00% higher than estimates for an EPS loss of $0.95 per share. The firm's loss per share narrowed by 94% since reporting a loss of $9.8 per share a year ago.

Revenues were upbeat at $30.7 million. That is an increase of 11.96% in revenues from the year-ago report and is 10.99% higher than consensus estimates set at $27.7 million.

The stock is up 19.79% to $2.30 after the report.

The firm's lower revenue growth to earnings signals that the firm has been able to reduce costs and improve its profit margin overall.

The average recommendation from Wall Street analysts was a Strong Buy which may get revised based on this new data.

Trading in the five days leading up to the report earned Aytu Biopharma Inc a Bullish Sentiment Rank from InvestorsObserver.

Prior to the report, InvestorsObserver gave the stock an overall score of 42. Meanwhile, the average Wall Street analyst rated the stock a Strong Buy.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan.